Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review.

IF 1.1 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Gauri Mukhiya, Dechao Jiao, Xinwei Han, Xueliang Zhou, Gaurab Pokhrel
{"title":"Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review.","authors":"Gauri Mukhiya,&nbsp;Dechao Jiao,&nbsp;Xinwei Han,&nbsp;Xueliang Zhou,&nbsp;Gaurab Pokhrel","doi":"10.25259/JCIS_130_2022","DOIUrl":null,"url":null,"abstract":"<p><p>Budd-Chiari syndrome is a complex clinical disorder of hepatic venous outflow obstruction, originating from the accessory hepatic vein (HV), large HV, and suprahepatic inferior vena cava (IVC). This disorder includes both HV and IVC obstructions and hepatopathy. This study aimed to conduct a systematic review of the survival rate and clinical success of different types of endovascular treatments for Budd-Chiari syndrome (BCS). All participant studies were retrieved from four databases and selected according to the eligibility criteria for systematic review of patients with BCS. The survival rate, clinical success of endovascular treatments in BCS, and survival rates at 1 and 5 years of publication year were calculated accordingly. A total of 3398 patients underwent an endovascular operation; among them, 93.6% showed clinical improvement after initial endovascular treatment. The median clinical success rates for recanalization, transjugular intrahepatic portosystemic shunt (TIPS), and combined procedures were 51%, 17.50%, and 52.50%, respectively. The median survival rates at 1 and 5 years were 51% and 51% for recanalization, 17.50% and 16% for TIPS, and 52.50% and 49.50% for combined treatment, respectively. Based on the year of publication, the median survival rates at 1 and 5 years were 23.50% and 22.50% before 2000, 41% and 41% in 2000‒2005, 35% and 35% in 2006‒2010, 51% and 48.50% in 2010‒2015, and 56% and 55.50% after 2015, respectively. Our findings indicate that the median survival rate at 1 and 5 years of recanalization treatment is higher than that of TIPS treatment, and recanalization provides better clinical improvement. The publication year findings strongly suggest progressive improvements in interventional endovascular therapy for BCS. Thus, interventional therapy restoring the physiologic hepatic venous outflow of the liver can be considered as the treatment of choice for patients with BCS which is a physiological modification procedure.</p>","PeriodicalId":15512,"journal":{"name":"Journal of Clinical Imaging Science","volume":"13 ","pages":"5"},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/0d/JCIS-13-5.PMC9899460.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Imaging Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/JCIS_130_2022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 1

Abstract

Budd-Chiari syndrome is a complex clinical disorder of hepatic venous outflow obstruction, originating from the accessory hepatic vein (HV), large HV, and suprahepatic inferior vena cava (IVC). This disorder includes both HV and IVC obstructions and hepatopathy. This study aimed to conduct a systematic review of the survival rate and clinical success of different types of endovascular treatments for Budd-Chiari syndrome (BCS). All participant studies were retrieved from four databases and selected according to the eligibility criteria for systematic review of patients with BCS. The survival rate, clinical success of endovascular treatments in BCS, and survival rates at 1 and 5 years of publication year were calculated accordingly. A total of 3398 patients underwent an endovascular operation; among them, 93.6% showed clinical improvement after initial endovascular treatment. The median clinical success rates for recanalization, transjugular intrahepatic portosystemic shunt (TIPS), and combined procedures were 51%, 17.50%, and 52.50%, respectively. The median survival rates at 1 and 5 years were 51% and 51% for recanalization, 17.50% and 16% for TIPS, and 52.50% and 49.50% for combined treatment, respectively. Based on the year of publication, the median survival rates at 1 and 5 years were 23.50% and 22.50% before 2000, 41% and 41% in 2000‒2005, 35% and 35% in 2006‒2010, 51% and 48.50% in 2010‒2015, and 56% and 55.50% after 2015, respectively. Our findings indicate that the median survival rate at 1 and 5 years of recanalization treatment is higher than that of TIPS treatment, and recanalization provides better clinical improvement. The publication year findings strongly suggest progressive improvements in interventional endovascular therapy for BCS. Thus, interventional therapy restoring the physiologic hepatic venous outflow of the liver can be considered as the treatment of choice for patients with BCS which is a physiological modification procedure.

Abstract Image

Abstract Image

Abstract Image

Budd-Chiari综合征患者血管内介入治疗的生存和临床成功:一项系统综述。
Budd-Chiari综合征是一种复杂的肝静脉流出梗阻的临床疾病,起源于肝副静脉(HV)、大静脉(HV)和肝上下腔静脉(IVC)。这种疾病包括肝炎和下腔静脉阻塞和肝病。本研究旨在对不同类型血管内治疗Budd-Chiari综合征(BCS)的生存率和临床成功率进行系统评价。所有参与研究均从四个数据库中检索,并根据BCS患者系统评价的资格标准进行选择。计算BCS患者的生存率、血管内治疗的临床成功率以及发表后1年和5年的生存率。共有3398例患者接受了血管内手术;其中93.6%的患者经血管内治疗后临床好转。再通、经颈静脉肝内门体分流术(TIPS)和联合手术的临床成功率中位数分别为51%、17.50%和52.50%。再通组1年和5年的中位生存率分别为51%和51%,TIPS组为17.50%和16%,联合治疗组为52.50%和49.50%。以发表年份为准,2000年前1年和5年的中位生存率分别为23.50%和22.50%,2000 - 2005年为41%和41%,2006-2010年为35%和35%,2010-2015年为51%和48.50%,2015年后为56%和55.50%。我们的研究结果表明,再通治疗1年和5年的中位生存率高于TIPS治疗,再通治疗可提供更好的临床改善。发表年的研究结果强烈表明介入血管内治疗BCS的进展性改进。因此,恢复肝脏生理性肝静脉流出的介入治疗可以被认为是BCS患者的治疗选择,这是一种生理修饰过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Imaging Science
Journal of Clinical Imaging Science RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
2.00
自引率
0.00%
发文量
65
期刊介绍: The Journal of Clinical Imaging Science (JCIS) is an open access peer-reviewed journal committed to publishing high-quality articles in the field of Imaging Science. The journal aims to present Imaging Science and relevant clinical information in an understandable and useful format. The journal is owned and published by the Scientific Scholar. Audience Our audience includes Radiologists, Researchers, Clinicians, medical professionals and students. Review process JCIS has a highly rigorous peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts, affiliations and financial associations such that the published content is not biased.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信